In a constantly evolving oncology environment, ESMO continues to expand its educational offer and conference portfolio and is pleased to announce that as of 2018 ESMO is taking on the TAT Congress, which will now be held on an annual basis in Europe.
The goals and the design of phase 1 studies have changed from just safety/toxicity to now include clinical activity/response and biomarker research. This new phase 1 paradigm has already led to rapid, conditional, approval of several new cancer therapeutics showing outstanding clinical activity in early-phase studies.
TAT focuses on early-phase development and translational research. The programme covered targeted agents, immuno-oncology and combinations involving such agents.
ESMO Press Release: Targeted Anticancer Therapies (TAT) Becomes an Annual ESMO Event
TAT 2018 Press Release: Epigenetics Therapy Shows Promise in Patients with Lymphoma
TAT 2018: Novel Study Explores the Genomic Landscape of Patients Achieving an Exceptional Response to Targeted Therapy
TAT 2018: Novel App Designed to Facilitate Biomarker-Driven Trials of Targeted Anti-Cancer Agents